DATED 24 October 2016Lease • November 10th, 2016 • Adaptimmune Therapeutics PLC • Biological products, (no disgnostic substances)
LR3. Parties to this lease Landlord MEPC MILTON PARK NO. 1 LIMITED (Company number 5491670) and MEPC MILTON PARK NO. 2 LIMITED (Company number 5491806), on behalf of MEPC Milton LP (LP No. LP14504), both of whose registered offices are at Lloyds Chambers 1 Portsoken Street London E1 8HZ Tenant ADAPTIMMUNE LIMITED (Company number 6456741) whose registered office is at 101 Park Drive Milton Park Abingdon Oxfordshire OX14 4RY Other parties ADAPTIMMUNE THERAPEUTICS PLC (Company number 9338148) whose registered office is at 101 Park Drive Milton Park Abingdon Oxfordshire OX14 4RY - Guarantor
STRATEGIC ALLIANCE AGREEMENTStrategic Alliance Agreement • November 10th, 2016 • Adaptimmune Therapeutics PLC • Biological products, (no disgnostic substances) • Texas
This Strategic Collaboration Agreement (“Agreement”), effective as of the 23rd day of September, 2016 (“Effective Date”), is entered into by and between The University of Texas M. D. Anderson Cancer Center, with a place of business located at 1515 Holcombe Blvd., Houston, TX 77030, USA (“MD Anderson”), a member institution of The University of Texas System (“System”) and Adaptimmune LLC, with a place of business located at 2001 Market Street, Philadelphia, PA 1903, USA (“Adaptimmune”); and Adaptimmune Limited, with a place of business at 101 Milton Park, Abingdon, Oxfordshire, OX14 4RY (“Adaptimmune Limited”) (MD Anderson and Adaptimmune each a “Party” and collectively the “Parties”).
CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT by and between Merck Sharp & Dohme B.V., and Adaptimmune Limited Dated: October 27th, 2016Clinical Trial Collaboration and Supply Agreement • November 10th, 2016 • Adaptimmune Therapeutics PLC • Biological products, (no disgnostic substances) • New York
This CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT (this “Agreement”), made as of October 27, 2016 (the “Effective Date”), is by and between Merck Sharp & Dohme B.V., having a place of business at Waarderweg 39, 2031 BN Haarlem, Netherlands (“Merck”), and Adaptimmune Limited, having a place of business at 101 Park Drive, Milton Park, Abingdon Oxfordshire, OX14 4RY, UK (“Adaptimmune”). Merck and Adaptimmune are each referred to herein individually as “Party” and collectively as “Parties”.
FIRST AMENDMENT TO EMPLOYMENT AGREEMENTEmployment Agreement • November 10th, 2016 • Adaptimmune Therapeutics PLC • Biological products, (no disgnostic substances)
THIS FIRST AMENDMENT TO EMPLOYMENT AGREEMENT (this “First Amendment”) is made effective (“Effective Date”) as of April 6, 2015, by and between Adaptimmune, LLC, a wholly-owned subsidiary of Adaptimmune Ltd. (“Company”), and Adrian Rawcliffe of Philadelphia, PA (“Executive”). Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to such terms in the Employment Agreement (as defined below).
SERVICES AGREEMENTServices Agreement • November 10th, 2016 • Adaptimmune Therapeutics PLC • Biological products, (no disgnostic substances) • New York
Services Agreement (the “Agreement”) dated as of September 13, 2016 (the “Execution Date”) is by and among ADAPTIMMUNE LIMITED (“Adaptimmune”), a limited company registered in England and Wales having its principal office at 101 Park Drive, Milton Business Park, Abingdon, Oxfordshire OX14 4RY, United Kingdom, ADAPTIMMUNE LLC, a Delaware limited liability company, having its principal office address at Two Commerce Square, Suite 1700, 2001 Market Street, Philadelphia, PA 19103, USA (“Client”) and PCT, LLC, A CALADRIUS COMPANY, a Delaware limited liability company having its principal office at 4 Pearl Court, Suite C, Allendale, New Jersey 07401 (“PCT”). Each of Adaptimmune, Client and PCT are referred to herein a “Party” and are collectively referred to as the “Parties”. This Agreement incorporates by reference the terms and conditions set forth in Attachment A (“Attachment A”) attached hereto and made a part hereof. Capitalized terms not otherwise defined herein will have the meaning s
To: CEO and CBO Adaptimmune LimitedTermination Agreement • November 10th, 2016 • Adaptimmune Therapeutics PLC • Biological products, (no disgnostic substances)
